Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial

por Kamm, Christian P., El-Koussy, Marwan, Humpert, Sebastian, Findling, Oliver, Burren, Yuliya, Schwegler, Guido, Donati, Filippo, Müller, Martin, Müller, Felix, Slotboom, Johannes, Kappos, Ludwig, Naegelin, Yvonne, Mattle, Heinrich P.
Publicado 2014

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1

por Wee, Edmund G., Moyo, Nathifa A., Saunders, Kevin O., LaBranche, Celia, Donati, Filippo, Capucci, Silvia, Parks, Robert, Borthwick, Nicola, Hannoun, Zara, Montefiori, David C., Haynes, Barton F., Hanke, Tomáš
Publicado 2019

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1

por Wee, Edmund G., Moyo, Nathifa A., Saunders, Kevin O., LaBranche, Celia, Donati, Filippo, Capucci, Silvia, Parks, Robert, Borthwick, Nicola, Hannoun, Zara, Montefiori, David C., Haynes, Barton F., Hanke, Tomáš
Publicado 2022

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial

por Kamm, Christian Philipp, El-Koussy, Marwan, Humpert, Sebastian, Findling, Oliver, von Bredow, Ferdinand, Burren, Yuliya, Schwegler, Guido, Schött, Dagmar, Donati, Filippo, Müller, Martin, Goebels, Norbert, Müller, Felix, Slotboom, Johannes, Tettenborn, Barbara, Kappos, Ludwig, Naegelin, Yvonne, Mattle, Heinrich Paul
Publicado 2012